Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.40 |
| ▸ | XDH | P47989 | 2/20 | 0.40 |
| ▸ | ULK1 | O75385 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | PLK4 | O00444 | 1/20 | 0.38 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.38 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | CLK2 | P49760 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4294423 | 0.83 | KDM4E (0.48) | CYP1A2MAPK1KDM4EALDH1A1HPGD | |
| SCHEMBL30418263 | 0.78 | XDH (0.44) | CYP1A2XDHMAPK1KDM4EGLA | |
| SCHEMBL25508045 | 0.78 | XDH (0.44) | CYP1A2XDHMAPK1KDM4EGLA | |
| SCHEMBL533320 | 0.78 | KDM4E (0.46) | CYP1A2MAPKAPK2XDHULK1PARP1 | |
| SCHEMBL19332290 | 0.77 | MAPT (0.45) | CYP1A2MAPKAPK2XDHULK1PARP1 | |
| SCHEMBL12388679 | 0.75 | HTR1A (0.43) | CYP1A2MAPKAPK2XDHULK1MAPK1 | |
| SCHEMBL6323401 | 0.75 | HTR1A (0.43) | CYP1A2MAPKAPK2XDHULK1KDM4E | |
| SCHEMBL13210017 | 0.73 | HTR1A (0.42) | CYP1A2MAPKAPK2XDHULK1PARP1 | |
| SCHEMBL6332160 | 0.72 | XDH (0.38) | CYP1A2MAPKAPK2XDHULK1KDM4E | |
| SCHEMBL3606511 | 0.71 | RAB9A (0.50) | CYP1A2XDHULK1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8465921-B2 | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | ELITECH HOLDING B.V. (NL) | 2013-06-18 | — | — | US | disclosed |
| US-20110275070-A1 | HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS | EPOCH PHARMACEUTICALS, INC. | 2011-11-10 | — | — | US | disclosed |
| CN-101914099-A | Covalently linked oligonucleotide minor groove binder conjugates | EPOCH BIOSCIENCES INC | 2010-12-15 | — | — | CN | disclosed |
| US-7794945-B2 | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | ELITECH HOLDING B.V. (NL) | 2010-09-14 | — | — | US | disclosed |
| US-7556923-B1 | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | EPOCH BIOSCIENCES, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-20090048427-A1 | HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS | EPOCH BIOSCIENCES, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| EP-0819133-B1 | COVALENTLY LINKED OLIGONUCLEOTIDE MINOR GROOVE BINDER CONJUGATES | EPOCH BIOSCIENCES INC (US) | 2008-01-02 | — | — | EP | disclosed |
| CN-1644585-A | Covalently linked oligonucleotide minor grove binder conjugates | EPOCH PHARMACEUTICALS INC (US) | 2005-07-27 | — | — | CN | disclosed |
| US-6884584-B2 | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | EPOCH BIOSCIENCES, INC. (US) | 2005-04-26 | — | — | US | disclosed |
| US-20050064463-A1 | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | DRUG ROYALTY LP1 (CA) | 2005-03-24 | — | — | US | disclosed |
| CN-1187363-C | Covalently bound oligonucleotide minor groove binder conjugates | IBORCH PHARMACEUTICAL CORP (US) | 2005-02-02 | — | — | CN | disclosed |
| US-20040058322-A1 | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | EPOCH PHARMACEUTICALS, INC. (US) | 2004-03-25 | — | — | US | disclosed |
| US-6492346-B1 | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | EPOCH PHARMACEUTICALS, INC. | 2002-12-10 | — | — | US | disclosed |
| US-6486308-B2 | NUCLEOTIDE SEQUENCE BINDING PARTICLES; FOR USE AS THERAPEUTIC AND DIAGNOSTIC TOOLS | EPOCH BIOSCIENCES, INC. | 2002-11-26 | — | — | US | disclosed |
| US-6426408-B1 | PLURALITY OF NUCLEOTIDE UNITS WITH LINKING GROUP | EPOCH BIOSCIENCES, INC. | 2002-07-30 | — | — | US | disclosed |
| US-20020052482-A1 | Covalently linked oligonucleotide minor grove binder conjugates | MICROPROBE | 2002-05-02 | — | — | US | disclosed |
| US-6312894-B1 | HYBRIDIZATION OF OLIGONUCLEOTIDES AND MINOR GROOVE BINDER COMBINATION; WHERE THE MINOR GROOVE BINDER BINDS IN A NON-INTERCALATING MANNER WITH A HIGHER ASSOCIATION CONSTANT | EPOCH PHARMACEUTICALS, INC. | 2001-11-06 | — | — | US | disclosed |
| US-6084102-A | THE OLIGONUCLEOTIDE IS COMPLEMENTARY TO A TARGET SEQUENCE OF SINGLE STRANDED OR DOUBLE STRANDED DNA, RNA OR HYBRIDS AND, WHEN USED AS A PROBE, BINDS MORE STRONGLY BECAUSE OF THE BOUND MINOR GROVE BINDER; MEDICAL DIAGNOSIS; ANTISENSE THERAPY | EPOCH PHARMACEUTICALS, INC. (US) | 2000-07-04 | — | — | US | disclosed |
| US-5801155-A | Covalently linked oligonucleotide minor grove binder conjugates | EPOCH PHARMACEUTICALS, INC. (US) | 1998-09-01 | — | — | US | disclosed |
| CN-1186496-A | Covalently bound oligonucleotide minor groove binder conjugates | IBORCH PHARMACEUTICAL CORP (US) | 1998-07-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052482-A1 | Covalently linked oligonucleotide minor grove binder conjugates | CD2BP2, MICA, SELPLG | CYP1A2 4497/4885MAPKAPK2 4606/4885XDH 4637/4885 |
| US-20050064463-A1 | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | DDB1, LIG3, MSH2 | CYP1A2 4837/4885MAPKAPK2 4559/4885XDH 4855/4885 |
| US-20090048427-A1 | HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS | DDB1, LIG3, MSH2 | CYP1A2 4837/4885MAPKAPK2 4559/4885XDH 4855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.